Neuralink to Perform Yearly Transplants of 20,000 Patients
Neuralink, the brain-computer interface company founded by Elon Musk, has revealed plans for the testing and release of its vision and Parkinson's disease chips. Here's a breakdown of the timeline and key details:
The Blindsight vision chip, designed to restore vision for blind individuals, has been tested only on monkeys so far. Neuralink aims to begin human implantations by 2030 1.
The Deep device, intended to treat neurological conditions like tremors and Parkinson’s disease, is part of Neuralink's roadmap alongside Blindsight and Telepathy (a brain-to-device communication chip). These projects are targeting regulatory approvals by 2029-2030 and clinical rollout through five large Neuralink clinics planned by 2030-2031. These clinics are expected to perform up to 20,000 surgeries a year by 2031 13.
Regulatory approval for the first commercial product, Telepathy, is expected by 2029, with Blindsight and Deep following shortly after 1. As of now, Neuralink’s human trials remain limited; fewer than 10 individuals have received implants, mainly for digital interface control. The bionic eye (Blindsight) human trial enrollment has not yet begun 1.
Neuralink projects $1 billion in annual revenue by 2031 from these brain implant products, based on an estimated $50,000 reimbursement per surgery 1.
Patients will have access to three versions of neurochips. One of these is for reducing symptoms of neurodegenerative diseases like Parkinson's 1.
It's important to note that as of mid-2025, the chip for vision and the device for Parkinson's have not yet been tested in humans. Regulatory approvals and actual human data are still pending 13.
Company representatives and Elon Musk did not respond to journalists' requests for comment. As of current reports, there are 10 patients with Neuralink chips undergoing clinical trials.
For more updates, follow Neuralink's official Telegram channel (@expert_mag).
- The Blindsight vision chip, designed to restore vision for blind individuals, and the Deep device, intended to treat neurological conditions like Parkinson’s disease, are part of Neuralink's future plans, targeted for regulatory approvals by 2029-2030 and clinical rollout through five large Neuralink clinics planned by 2030-2031.
- In the realm of health-and-wellness and medical-conditions, Neuralink projects to have three versions of neurochips, one of which is specifically designed to reduce symptoms of neurodegenerative diseases like Parkinson's.
- Although Neuralink's human trials remain limited, with fewer than 10 individuals having received implants, the company aims to begin human implantations for the Blindsight vision chip by 2030 and to have regulatory approval for its first commercial product, Telepathy, by 2029, with Blindsight and Deep following shortly after.
